^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BRL-301

    i
    Other names: BRL-301, CD19-UCART, BRL301, BRL 301, TyU19
    Associations

    News

    Trials
    Company:
    BRL Medicine
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    9d
    Universal CAR-T Cell Therapy for NHL (clinicaltrials.gov)
    P=N/A, N=6, Recruiting, Bioray Laboratories
    New trial
    |
    BRL-301
    1year
    Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases (clinicaltrials.gov)
    P=N/A, N=15, Enrolling by invitation, Bioray Laboratories | Recruiting --> Enrolling by invitation
    Enrollment status • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    BRL-301
    almost2years
    Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus Erythematosus (clinicaltrials.gov)
    P=N/A, N=12, Recruiting, Bioray Laboratories | Not yet recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy
    |
    CD19 expression
    |
    BRL-301
    over2years
    U-CART: Safety and Efficacy Evaluation of CD19-UCART (clinicaltrials.gov)
    P=N/A, N=20, Suspended, Bioray Laboratories | Trial primary completion date: Jun 2023 --> Dec 2023
    Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive • CD19 expression
    |
    cyclophosphamide • BRL-301
    almost3years
    Safety and Efficacy Evaluation of Next-generation CD19-UCART (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Bioray Laboratories | Initiation date: Dec 2022 --> Dec 2023
    Trial initiation date • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    cyclophosphamide • BRL-301
    almost3years
    U-CART: Safety and Efficacy Evaluation of CD19-UCART (clinicaltrials.gov)
    P=N/A, N=20, Suspended, Bioray Laboratories | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Jun 2023
    Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive • CD19 expression
    |
    cyclophosphamide • BRL-301
    3years
    Safety and Efficacy Evaluation of Next-generation CD19-UCART (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Bioray Laboratories | Initiation date: Jun 2022 --> Dec 2022
    Trial initiation date • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    cyclophosphamide • BRL-301
    3years
    U-CART: Safety and Efficacy Evaluation of CD19-UCART (clinicaltrials.gov)
    P=N/A, N=20, Suspended, Bioray Laboratories | Recruiting --> Suspended
    Trial suspension
    |
    CD19 (CD19 Molecule)
    |
    cyclophosphamide • BRL-301
    over3years
    Safety and Efficacy Evaluation of Next-generation CD19-UCART (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Bioray Laboratories
    New P1 trial • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    cyclophosphamide • BRL-301
    over3years
    U-CART: Safety and Efficacy Evaluation of CD19-UCART (clinicaltrials.gov)
    P=N/A, N=20, Recruiting, Bioray Laboratories | Trial primary completion date: Dec 2021 --> Dec 2022
    Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    cyclophosphamide • BRL-301
    almost5years
    U-CART: Safety and Efficacy Evaluation of CD19-UCART (clinicaltrials.gov)
    P=N/A, N=20, Recruiting, Bioray Laboratories | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    BRL-301
    over5years
    U-CART: Safety and Efficacy Evaluation of CD19-UCART (clinicaltrials.gov)
    P=N/A, N=20, Recruiting, Shanghai Bioray Laboratory Inc. | Trial primary completion date: Aug 2020 --> Dec 2020
    Clinical • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    BRL-301